Prognostic value of the standardized uptake value in esophageal cancer

American Journal of Roentgenology

Volumn 185, Issue 2, 2005, Pages 436-440

  Van Westreenen, Henderik L ^a   Plukker, John T M ^a   Cobben, David C P ^a   Verhoogt, Carolien J M ^a   Groen, Henk ^a   Jager, Pieter L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; MALE; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; ESOPHAGUS TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SCINTISCANNING; SURVIVAL RATE;

AGED; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE;

EID: 25644443260     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.185.2.01850436     Document Type: Article

References (19)

1. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42[suppl 5]:1S-93S
2. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratomoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996; 37:1042-1047
3. Lowe VJ, Naunheim KS. Current role of positron mission tomography in thoracic oncology. Thorax 1998; 53:703-712
4. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000; 27:647-655
5. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83:918-924
6. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F] -D-glucose. Cancer 1998; 82:2227-2234
7. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002; 4:99-104
8. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18:3202-3210
9. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998; 78:521-527
10. Rasanen JV, Sihvo EI, Knuuti MJ, et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003; 10:954-960
11. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998; 39:1002-1007
12. Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002; 94:921-928
13. Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th ed. New York, NY: Wiley & Sons, 2003
14. Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med 199; 26:591-598
15. Kato H, Takita J, Miyazaki T, et al. Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res 2002; 22:2635-2639
16. Kato H, Takita J, Miyazaki T, et al. Correlation of 18-F- fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 2003; 23:3263-3272
17. Phay JE, Hussain HB, Moley JF. Strategy for identification of novel glucose transporter family members by using internet-based genomic databases. Surgery 2000; 128:946-951
18. Younes M, Pathak M, Finnie D, Sifers RN, Liu Y, Schwartz MR. Expression of the neutral amino acids transporter ASCT1 in esophageal carcinomas. Anticancer Res 2000; 20:3775-3779
19. Menzel Ch, Dobert N, Rieker O, et al. 18F-deoxyglucose PET for the staging of oesophageal cancer: influence of histopathological subtype and tumour grading [in German]. Nuklearmedizin 2003; 42:90-93